The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients in the PRA023 group achieved clinical remission at 12 weeks vs. placebo (26.5% ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, ...

A 52-week phase 3 clinical trial of Skyrizi, or risankizumab — a drug initially approved to treat Crohn’s disease, psoriatic arthritis and psoriasis — was shown to also achieve clinical remission in ...

Ease the symptoms of a UC flare, such as diarrhea, abdominal pain, and fever using expert-backed tips, and learn when to seek ...

Learn how prebiotics, or foods with compounds that support a healthy balance of gut bacteria (microbiome), may benefit people ...

The MarketWatch News Department was not involved in the creation of this content. Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and ...